Company: SXTPW
Filing Date: 2025-09-02
Form Type: DEFR14A
Source: 0001213900-25-082789
Chunk: 25

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-02
Form: DEFR14A
Chunk 25
---
 | 2023 |     |        |       - |     |            |       - |     |             |      - |     |        |      - |     |           |       - |
|                                              |     | 2022 |     |        |       - |     |            |       - |     |             |      - |     |        |      - |     |           |       - |

| (1) | We periodically review, and may increase, base salaries in accordance                
 with our normal annual compensation review for each of our named executive officers. |

Equity Awards On July 12, 2023, Dr. Dow was granted a five-year option to purchase a total of 250 shares of our common stock on the last day of each quarter in each calendar year (for a cumulative total or no more than 5,000 shares over five years) and (ii) Mr. Miller was granted a five-year option to purchase a total of 200 shares of our common stock on the last day of each quarter in each calendar year (for a cumulative total or no more than 4,000 shares over five years). The per share exercise price of the options were initially equal to the per share closing price of our common stock on the date of grant and had a cashless exercise provision. In November 2023, the Board reset the exercise price of the options to be equal to $60.00 and modified the vesting provisions of the option to vest annually over five years, rather than quarterly, with the first vesting date being December 31, 2024. The initial grant and subsequent amendment of these options was contingent upon the stockholders of the Company approving the amendment to the exercise price of the options and approving the amendment to the 2022 Plan to increase the number of shares available under the 2022 Plan in order to comply with Listing Rule 5635(c) of The Nasdaq Stock Market LLC. On July 16, 2024, the Company’s stockholders approved the proposal to increase the number of shares available under the 2022 Plan. As of that date, Dr. Dow and Mr. Miller’s option grants, as subsequently amended, were considered effective. In February 2024, subject to and contingent upon the stockholders of the Company approving the amendment to the 2022 Plan to increase the number of shares available under the 2022 Plan, we granted Ms. Landon a five-year option to purchase a total of 4,167 shares of